Mercado mundial de detección de drogas: tendencias de la industria y pronóstico hasta 2031

Análisis y tamaño del mercado de detección de drogas

En el ámbito deportivo y atlético, el control de drogas es una herramienta fundamental para mantener la equidad, la integridad y la seguridad. Las organizaciones deportivas emplean protocolos de pruebas rigurosos para detectar el uso de sustancias prohibidas o drogas que mejoran el rendimiento entre los atletas. Esto garantiza la igualdad de condiciones al disuadir las prácticas de dopaje y mantener la integridad de las competiciones. El control de drogas no solo promueve los estándares éticos, sino que también protege la salud y el bienestar de los atletas, ya que el uso de ciertas sustancias puede suponer graves riesgos para la salud.

El tamaño del mercado mundial de detección de drogas se valoró en USD 7.30 mil millones en 2023 y se proyecta que alcance los USD 26.15 mil millones para 2031, con una CAGR del 17,30% durante el período de pronóstico de 2024 a 2031. Además de los conocimientos sobre escenarios de mercado como el valor de mercado, la tasa de crecimiento, la segmentación, la cobertura geográfica y los principales actores, los informes de mercado seleccionados por Data Bridge Market Research también incluyen un análisis profundo de expertos, epidemiología del paciente, análisis de la cartera, análisis de precios y marco regulatorio.

Segmentación y alcance del mercado de detección de drogas      

Market Definition

Drug screening is a process used to detect the presence of drugs or their metabolites in biological samples such as urine, blood, saliva, or hair. It is commonly employed in various settings including workplaces, healthcare facilities, sports organizations, and law enforcement agencies to assess drug use or compliance with drug treatment programs.

Drug Screening Market Dynamics

Drivers

• Increased Drug and Alcohol Consumption Growing Demand for Drug Screening Measures

This rise in consumption has heightened concerns about safety, productivity, and public health, necessitating stringent screening protocols. Consequently, the drug screening market is witnessing a surge as organizations seek reliable methods to detect substance abuse among individuals. This trend is driving innovation in drug screening technologies, leading to the development of more accurate and efficient testing solutions. As a result, the drug screening market is projected to experience continued expansion in response to the escalating challenges posed by substance abuse.

According to the World Drug Report 2021 published by UNODC highlights a concerning trend with a 22% increase in global drug usage. Notably, cannabis consumption is significant, with approximately 200 million users worldwide, representing 4% of the global population. This surge in drug use underscores the urgent need for robust drug screening measures across various sectors to address health, safety, and societal implications effectively.

• Rise in Government Funding Fosters Pharmaceutical Development

Through government initiatives such as grants, subsidies, and research funding, governments incentivize drug discovery and development processes. These funds support various stages of drug screening, from early research to clinical trials, facilitating the identification of potential therapeutics. Government-backed programs often prioritize areas of public health concern, driving innovation and investment in drug screening technologies. Pharmaceutical companies and research institutions actively engage in drug screening activities to capitalize on available funding opportunities, thus stimulating the growth of the drug screening market.

Opportunities

• Rising Technological Advancements Enhances the Predictive Power of Drug Screening Processes

Recent technological advancements in drug screening, such as high-throughput screening (HTS) methods, microfluidics, and advanced imaging techniques, have revolutionized the drug screening market. These innovations allow for faster, more accurate, and cost-effective screening of potential drug candidates. The integration of artificial intelligence (AI) and machine learning algorithms further enhances the efficiency and predictive power of drug screening processes. This presents a significant opportunity for the drug screening market to expand, catering to the growing demand for novel therapeutics and personalized medicine.

• Rising Substance Abuse Issues Promotes the Adoption of Effective Drug Screening Solutions

As organizations strive to maintain safety standards and productivity in workplaces, schools, and healthcare settings, the demand for reliable drug screening methods is escalating. This presents a significant opportunity for the drug screening market to expand its offerings, catering to diverse industries with innovative testing technologies. With advancements in drug detection techniques, including rapid testing kits and sophisticated laboratory-based analyses, the market is poised for growth.

Restraints/Challenges

• Rising False Positive and Negative Results in Drug Screening limits the Screening Process

False positives occur when a test wrongly identifies a substance as present, potentially leading to unnecessary concerns or actions. Conversely, false negatives arise when a test fails to detect a substance that is actually present, posing risks of undetected drug use. These errors undermine the reliability of drug screening results, leading to diminished confidence in the screening process. Consequently, false positives may result in unwarranted consequences such as unnecessary treatment or sanctions, while false negatives could lead to overlooking substance abuse issues.

• Rise in Privacy Concerns Limits the Expansion of Drug Screening Practices

Employers and regulatory bodies face increasing scrutiny over the invasion of privacy rights through extensive drug testing practices. Heightened awareness of individual rights and data protection regulations demands more transparent and ethically sound testing methodologies, often requiring explicit consent from individuals. The fear of discrimination or stigmatization based on test results further complicates the implementation of widespread screening programs.

This drug screening market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the drug screening market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In December 2022, PhoreMost Ltd. and ThinkCyte K.K announced a strategic research partnership to advance phenotypic drug screening using artificial intelligence (AI). Combining PhoreMost's expertise in phenotypic screening with ThinkCyte's AI capabilities, the collaboration aims to accelerate drug discovery processes, potentially yielding novel therapeutics
• In April 2022, Saladax Biomedical, Inc acquired a patent portfolio for antipsychotic drug testing from Janssen Pharmaceutica NV, encompassing 17 patent families. This acquisition, resulting in 33 U.S. patents and 296 international patents, strengthens Saladax's position in the field of antipsychotic drug testing, potentially leading to improved patient care
• In August 2021, Select Health of South Carolina and Quest Diagnostics collaborated to expand Select Health's laboratory network, enhancing access to diagnostic information services for Medicaid and Medicare-Medicaid dual-eligible enrollees. This partnership aims to improve healthcare outcomes by increasing members' access to vital diagnostics
• In May 2020, Psychemedics Corporation launched a Vaping Panel designed to detect Marijuana, CBD, and Nicotine usage. This innovative test fills a critical need for schools and businesses to identify drug ingestion, including through electronic cigarettes, addressing growing concerns about substance abuse

Drug Screening Market Scope

The drug screening market is segmented on the basis of product and services, sample type, and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product and Services

• Equipment
• Liquid Analytical Instruments
• Breathalyzers
• Fuel Cell Breathalyzers
• Semiconductor Breathalyzers
• Other Breathalyzers
• Immunoassay Analyzers
• Chromatography Instruments
• Rapid Testing Devices (RTD)
• Urine Testing Devices
• Drug Testing Cups
• Dip Cards
• Drug Testing Cassettes
• Consumables
• Assay Kits
• Sample Collection Devices
• Calibrators and Controls
• Other Consumables
• Drug screening
• Liquid Analytical Instruments
• Laboratory Services

Sample Type

• Oral Fluid or Saliva
• Breath
• Hair
• Urine
• Other Samples

End User

• Workplace and Schools
• Criminal Justice Systems and Law Enforcement Agencies
• Drug Testing Laboratories
• Drug Treatment Centers
• Hospitals, Personal Users
• Pain Management Centers
• Individual Users
• Colleges

Drug Screening Market Regional Analysis/Insights

The drug screening market is analyzed, and market size insights and trends are provided by country, product and services, sample type, and end user, as referenced above.

The countries covered in the drug screening market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and rest of South America as part of South America.

North America dominates the drug screening market due to the increasing consumption of illegal drugs in the region has led to a growing demand for drug screening services and the availability of government backing and funding to control drug abuse has facilitated the growth of the drug screening market. The rules and regulations encouraging drug screening within the region have also contributed to the market's expansion.

The Asia-Pacific region is expected to witness significant growth in workplace safety and employee well-being during the forecast period. This growth is attributed to increasing awareness of the importance of safety and health at work, as well as the commitment of governments, workers, and employers to ensure and promote a safe and healthy working environment for all workers in all workplaces. The International Labour Organization (ILO) plays a crucial role in fostering a preventative safety and health culture by strengthening national occupational safety and health (OSH) systems, including legal and policy frameworks, compliance mechanisms, occupational accident and disease reporting, awareness campaigns, and capacity building.

La sección de países del informe también proporciona factores de impacto de mercado individuales y cambios en la regulación en el mercado a nivel nacional que afectan las tendencias actuales y futuras del mercado. Los puntos de datos como el análisis de la cadena de valor aguas abajo y aguas arriba, las tendencias técnicas y el análisis de las cinco fuerzas de Porter, los estudios de casos son algunos de los indicadores utilizados para pronosticar el escenario del mercado para países individuales. Además, la presencia y disponibilidad de marcas globales y sus desafíos enfrentados debido a la competencia grande o escasa de las marcas locales y nacionales, el impacto de los aranceles nacionales y las rutas comerciales se consideran al proporcionar un análisis de pronóstico de los datos del país.

Crecimiento de la infraestructura de atención de salud Base instalada y penetración de nuevas tecnologías

El mercado de detección de drogas también le proporciona un análisis detallado del mercado para cada país: crecimiento del gasto sanitario en equipos de capital, base instalada de diferentes tipos de productos para el mercado de detección de drogas, impacto de la tecnología mediante curvas de línea de vida y cambios en los escenarios regulatorios de la atención médica y su impacto en el mercado de detección de drogas. Los datos están disponibles para el período histórico 2016-2021.

Análisis del panorama competitivo y del mercado de detección de drogas

El panorama competitivo del mercado de detección de drogas proporciona detalles por competidor. Los detalles incluidos son una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en investigación y desarrollo, las nuevas iniciativas de mercado, la presencia global, los sitios e instalaciones de producción, las capacidades de producción, las fortalezas y debilidades de la empresa, el lanzamiento de productos, la amplitud y variedad de productos, el dominio de la aplicación. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de las empresas en relación con el mercado de detección de drogas.

Algunos de los principales actores que operan en el mercado de detección de drogas son:

• LabCorp (Estados Unidos)
• Quest Diagnostics (Estados Unidos)
• Abbott (Estados Unidos)
• Thermo Fisher Scientific, Inc. (Estados Unidos)
• Alfa Scientific Designs, Inc. (Estados Unidos)
• OraSure Technologies, Inc. (Estados Unidos)
• Siemens (Alemania)
• F. Hoffmann-La Roche Ltd (Suiza)
• MPD Inc. (Estados Unidos)
• Corporación Shimadzu (Japón)
• Lifeloc Technologies, Inc. (Estados Unidos)
• Drägerwerk AG & Co. KGaA (Alemania)
• Premier Biotech, Inc. (Estados Unidos)
• Laboratorios Omega, Inc. (Estados Unidos)
• Corporación Psychemedics (Estados Unidos)
• Laboratorio de Referencia Clínica Inc. (Estados Unidos)
• Corporación Biomédica Americana (Estados Unidos)
• Laboratorios globales de ACM (Estados Unidos)
• Sciteck, Inc. (Estados Unidos)
• Synens SAS (Francia)
• Intoxicómetros (EE. UU.)
• AccuSource Inc., (Estados Unidos)
• Soluciones sanitarias Cordant (Estados Unidos)
• Salud del Milenio (Estados Unidos)

SKU-1628